Viking Therapeutics (LTS:0VQA) Moat Score: 4/10 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0VQA Viking Therapeutics Inc LTS:0VQA
31 GF Score
Price $37.82
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Moat Score?

Viking Therapeutics LTS:0VQA +1.70% 31 Moat Score is 4 as of Jul. 22, 2026. GuruFocus rates LTS:0VQA with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,396 Biotechnology companies, Viking Therapeutics ranks better than 88.83% on this metric.

Viking Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Viking Therapeutics has Narrow Moat: Viking Therapeutics Inc has a discernible but modest moat due to its focus on innovative drug development and valuable patents. However, the biotech industry is highly competitive, and the company faces significant regulatory hurdles and market competition.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Viking Therapeutics might have Narrow Moat - Discernible but modest moat.

Viking Therapeutics  (LTS:0VQA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Viking Therapeutics Moat Score Related Terms

LTS:0VQA vs EWTX, ACAD, DNLI: Moat Score Comparison

For the Biotechnology subindustry, Viking Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Moat Score falls into.


LTS:0VQA
31GF Score
Viking Therapeutics Inc LTS:0VQA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Viking Therapeutics (LTS:0VQA) has a Moat Score of 4 as of Jul. 22, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Viking Therapeutics ranks #156 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Viking Therapeutics' Moat Score too high?
Viking Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Viking Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Viking Therapeutics ranks #156 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viking Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Moat Score compare to EWTX and ACAD?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #156 out of 1396 companies for Moat Score. This places Viking Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Viking Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viking Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viking Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (LTS:0VQA) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Viking Therapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Viking Therapeutics (LTS:0VQA), the current Moat Score is 4 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
31GF Score

Get the complete analysis for LTS:0VQA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.82
Price